Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio
Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held...
Amgen
Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...
Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...
Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance
US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...
BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights
On August 26, 2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had...
Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales
US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9%...
Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...
BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...
Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment
US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...
Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales
US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...
Amgen Announces $900M Investment to Expand Ohio Manufacturing
US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...
Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...
Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer
US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...
Amgen’s Uplizna Approved by FDA for IgG4-Related Disease
US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...
Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars
South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...
Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth
Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion...
FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC
US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...
GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment
Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...